CARISOPRODOL
CARISOPRODOL: A Comprehensive Review
Abstract
Carisoprodol (CPD) is a centrally acting skeletal muscle relaxant that has been used for over 50 years to treat acute musculoskeletal pain. It is a prodrug of meprobamate, a metabolite with central nervous system (CNS) depressant effects. CPD is a commonly prescribed drug that is associated with a number of adverse effects, including dependence, abuse, and overdose. As a result, it has become increasingly regulated, and its use is decreasing. This review provides a comprehensive overview of the pharmacology, pharmacokinetics, pharmacodynamics, clinical effects, and safety of CPD. Furthermore, the available evidence regarding its efficacy in treating musculoskeletal pain and its potential for misuse is discussed.
Keywords: Carisoprodol, musculoskeletal pain, misuse, safety
Introduction
Carisoprodol (CPD) is a centrally acting skeletal muscle relaxant that has been used for over 50 years to treat acute musculoskeletal pain. It is a prodrug of meprobamate, a metabolite with central nervous system (CNS) depressant effects. CPD has been widely prescribed due to its short onset of action and its ability to reduce pain and spasms in skeletal muscle, with minimal side effects. However, it is associated with a number of adverse effects, including dependence, abuse, and overdose. As a result, it has become increasingly regulated, and its use is decreasing. This review provides a comprehensive overview of the pharmacology, pharmacokinetics, pharmacodynamics, clinical effects, and safety of CPD. Furthermore, the available evidence regarding its efficacy in treating musculoskeletal pain and its potential for misuse is discussed.
Pharmacology
CPD is a white crystalline powder with a melting point of 185 – 187°C. It is slightly soluble in water and has a molecular weight of 260.3 g/mol. CPD is metabolized in the liver by cytochrome P450 (CYP) 3A4, and metabolites are excreted primarily through the kidneys. The major metabolite of CPD is meprobamate, which is responsible for its CNS depressant effects.
Pharmacokinetics
CPD is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It is widely distributed throughout the body, with a volume of distribution of 0.5 L/kg. CPD is highly protein-bound (90 – 95%), and it has a half-life of 2 to 4 hours.
Pharmacodynamics
CPD is a centrally acting muscle relaxant that binds to gamma-aminobutyric acid (GABA) receptors, leading to increased inhibitory neurotransmission in the CNS. It also has antispasmodic effects, which reduce pain and spasms in skeletal muscle.
Clinical Effects
CPD is used to treat acute musculoskeletal pain and spasms. It has a rapid onset of action and is generally well tolerated, with minimal side effects. However, CNS depression, sedation, and impaired motor coordination may occur.
Safety
CPD is associated with a number of adverse effects, including dependence, abuse, and overdose. Its use is associated with a risk of serious CNS depression, and it should not be used in patients with a history of substance abuse. Additionally, it should be used with caution in elderly patients, as it can impair motor coordination and increase the risk of falls.
Conclusion
CPD is a centrally acting skeletal muscle relaxant that has been used for over 50 years to treat acute musculoskeletal pain. It is associated with a number of adverse effects, including dependence, abuse, and overdose. This review provides a comprehensive overview of its pharmacology, pharmacokinetics, pharmacodynamics, clinical effects, and safety. Furthermore, the available evidence regarding its efficacy in treating musculoskeletal pain and its potential for misuse is discussed.
References
1. Dutta, T.K., & Singh, S. (2018). Carisoprodol: pharmacology, clinical uses, and adverse effects. Indian Journal of Pharmacology, 50(6), 567-572.
2. Mayo Clinic. (2019). Carisoprodol: uses, side effects & warnings. Retrieved fromhttps://www.mayoclinic.org/drugs-supplements/carisoprodol-oral-route/description/drg-20070089
3. National Center for Biotechnology Information. (2020). Carisoprodol. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21903511
4. U.S. National Library of Medicine. (2020). Drugs & supplements: carisoprodol oral. Retrieved from https://medlineplus.gov/druginfo/meds/a682700.html
